To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
RWJ-51204 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.
Additional recommended knowledge
RWJ-51204 is a nonselective partial agonist at GABAA receptors. It produces primarily anxiolytic effects at low doses, with sedative, ataxia and muscle relaxant effects only appearing at some 20x the effective anxiolytic dose. It was developed by the pharmaceutical company Johnson & Johnson in 1998, but its current progress is unknown.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "RWJ-51204". A list of authors is available in Wikipedia.|